期刊论文详细信息
Cardiovascular Diabetology
Circulating long chain acylcarnitines and outcomes in diabetic heart failure: an HF-ACTION clinical trial substudy
G. Michael Felker1  Olga Ilkayeva2  Christopher B. Newgard2  Stephanie N. Giamberardino2  James Bain2  Robert W. McGarrah3  Jessica A. Regan3  William E. Kraus3  Lauren K. Truby3  Svati H. Shah4  Christopher M. O’Connor5 
[1] Department of Medicine, Division of Cardiology, Duke University School of Medicine, Durham, NC, USA;Duke Molecular Physiology Institute, Duke University Medical Center, 27710, Durham, NC, USA;Duke Molecular Physiology Institute, Duke University Medical Center, 27710, Durham, NC, USA;Department of Medicine, Division of Cardiology, Duke University School of Medicine, Durham, NC, USA;Duke Molecular Physiology Institute, Duke University Medical Center, 27710, Durham, NC, USA;Department of Medicine, Division of Cardiology, Duke University School of Medicine, Durham, NC, USA;Precision Genomics Collaboratory, Duke University School of Medicine, Durham, USA;Inova Heart and Vascular Institute, Falls Church, NC, USA;
关键词: Heart failure;    Diabetes;    Exercise;    Long chain acylcarnitines;   
DOI  :  10.1186/s12933-021-01353-z
来源: Springer
PDF
【 摘 要 】

BackgroundWhether differences in circulating long chain acylcarnitines (LCAC) are seen in heart failure (HF) patients with and without diabetes mellitus (DM), and whether these biomarkers report on exercise capacity and clinical outcomes, remains unknown. The objective of the current study was to use metabolomic profiling to identify biomarkers that report on exercise capacity, clinical outcomes, and differential response to exercise in HF patients with and without DM.MethodsTargeted mass spectrometry was used to quantify metabolites in plasma from participants in the heart failure: a controlled trial investigating outcomes of exercise training (HF-ACTION) trial. Principal components analysis was used to identify 12 uncorrelated factors. The association between metabolite factors, diabetes status, exercise capacity, and time to the primary clinical outcome of all-cause mortality or all-cause hospitalization was assessed.ResultsA total of 664 participants were included: 359 (54%) with DM. LCAC factor levels were associated with baseline exercise capacity as measured by peak oxygen consumption (beta 0.86, p  =  2 × 10−7, and were differentially associated in participants with and without DM (beta 1.58, p  =  8  ×  10−8 vs. 0.67, p  =  9  ×  10−4, respectively; p value for interaction  =  0.012). LCAC levels changed to a lesser extent in participants with DM after exercise (mean ∆ 0.09, p  =  0.24) than in those without DM (mean ∆ 0.16, p  =  0.08). In univariate and multivariate modeling, LCAC factor levels were associated with time to the primary outcome (multivariate HR 0.80, p  =  2.74  ×  10−8), and were more strongly linked to outcomes in diabetic participants (HR 0.64, p  =  3.21  ×  10−9 v. HR 0.90, p  =  0.104, p value for interaction  =  0.001). When analysis was performed at the level of individual metabolites, C16, C16:1, C18, and C18:1 had the greatest associations with both exercise capacity and outcomes, with higher levels associated with worse outcomes. Similar associations with time to the primary clinical outcome were not found in a control group of patients without HF from the CATHeterization GENetics (CATHGEN) study.ConclusionsLCAC biomarkers are associated with exercise status and clinical outcomes differentially in HF patients with and without DM. Impaired fatty acid substrate utilization and mitochondrial dysfunction both at the level of the skeletal muscle and the myocardium may explain the decreased exercise capacity, attenuated response to exercise training, and poor clinical outcomes seen in patients with HF and DM.Trial Registration clinicaltrials.gov Identifier: NCT00047437.

【 授权许可】

CC BY   

【 预 览 】
附件列表
Files Size Format View
RO202109177682459ZK.pdf 813KB PDF download
  文献评价指标  
  下载次数:18次 浏览次数:3次